Instituted Grounds Can be Supported with New Evidence Not Present in Petition/Institution Decision
Within the past week, the Court of Appeals for the Federal Circuit (CAFC) has issued two significant opinions on AIA trial practice—both of which explain the critical import of the Administrative Procedure Act (APA). As discussed earlier this week, 5 U.S.C. § 554(b)(3) prevents the Patent Trial & Appeal Board (PTAB) from introducing new claim interpretation theories without notice, or opportunity to respond in SAS Institute Inc., v. ComplemenSoft LLC. On the heels of that decision comes perhaps an even more significant decision in Genzyme Therapeutic Products LP v. BioMarin Pharmaceutical Inc.
In Genzyme, the Court dispelled a widely held belief held by many practitioners and PTAB judges alike. Namely, that an AIA trial petition must function as a storehouse for all possible evidence and arguments. In a plainly worded opinion the Federal Circuit found that “[t]he purpose of the trial in an inter partes review proceeding is to give the parties an opportunity to build a record by introducing evidence—not simply to weigh evidence of which the Board is already aware.” (emphasis added) (here)
Simply stated, this decision is an AIA trial practice game changer.
Continue Reading CAFC Makes Clear New Evidence During AIA Trials is Expected